University of Tennessee - Knoxville

University of Tennessee - Knoxville

University of Tennessee - Knoxville

Overview
Date Founded

1794

Headquarters

301 Andy Holt Tower,Knoxville, TN 37966-0100

Charitable Causes

Education Research & Support

Employees (Worldwide)

12K

Industries

Schools & Student Services

Company Description

The University of Tennessee (also referred to as the University of Tennessee, Knoxville, UT Knoxville, UT, or UTK) is a public sun-grant and land-grant university headquartered at Knoxville, Tennessee, United States. Founded in 1794, two years before Tennessee entered the Union as the 16th state, it is the flagship institution of the statewide University of Tennessee system with nine undergraduate colleges and eleven graduate colleges and hosts almost 28,000 students from all 50 states and more than 100 foreign countries.

Contact Data
Trying to get in touch with decision makers at University of Tennessee - Knoxville? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees
Board of Directors

President & Chief Executive Officer at Knoxville Utilities Board

Executive Director at University of Tennessee - Knoxville

President at South Central Communications Corp.

Chief Operating Officer at Cellular Sales of Knoxville, Inc.

Distinguished Alumni
Min Kao is now Co-Founder at Garmin Ltd.
Gary W. Rollins is now Chairman & Chief Executive Officer at Rollins, Inc.
Paths to University of Tennessee - Knoxville
Potential Connections via
Relationship Science
You
University of Tennessee - Knoxville
Advisors & Consultants
Real Estate Agent

Realtor Associate at Hobson Realtors

Clients

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.

Veru, Inc. is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects; and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Healthcare delivery operating a public charity hospital providing inpatient and outpatient services

Key Stats and Financials As of 2020
Market Capitalization
Total Enterprise Value
Earnings Per Share
Revenue
$1.02B
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Suppliers
TZ Limited Other Manufacturing | Sydney, Australia

TZ Ltd. operates as a smart lock technology company which engages in the provision of developing and licensing propriety technologies. The firm operates through its sole segment of development and commercialization of hardware and software products in the United States, Australia, Europe Middle East and Africa, and Asia markets. Its TZ SMArt Devices such as TZ CabLock, TZ BeamLock, TZ Radial, and TZ SwingHandle can be used around the home for managing: Medicine cabinets and drawers, Hazardous cleaning chemical cabinets, Pool gates, and Fences. The company was founded by Dickory Rudduck in 1986 and is headquartered in Sydney, Australia.

Awards & Honors
Rank #194
2010
The Chronicle of Philanthropy - Philanthropy 400
Rank #203
2009
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by University of Tennessee - Knoxville. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of University of Tennessee - Knoxville's profile does not indicate a business or promotional relationship of any kind between RelSci and University of Tennessee - Knoxville.